作为选择性HDAC1/2抑制剂的β-carboline衍生物的设计,合成和抗瘤活性研究

Zhiya Wang1, Limeng Wu2, Kaisi Yang2

  • 1Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China; School of Pharmacy, China Medical University, Shenyang 110122, People's Republic of China.

Bioorganic chemistry
|July 24, 2025
PubMed
概括

基于β-卡博林的新型HDAC抑制剂,特别是ZWZH-21,通过向HDAC1/2.2,对结直肠癌产生强大的抗瘤作用. 这种化合物有效地抑制癌细胞的生长,迁移,并诱导亡,具有有希望的疗效和低毒性.